{"id":583,"date":"2024-03-24T14:11:59","date_gmt":"2024-03-24T14:11:59","guid":{"rendered":"https:\/\/pureoptical.com\/?p=583"},"modified":"2024-04-23T15:25:21","modified_gmt":"2024-04-23T15:25:21","slug":"areds1-vs-areds2","status":"publish","type":"post","link":"https:\/\/pureoptical.com\/blog\/areds1-vs-areds2\/","title":{"rendered":"What Is The Difference Between AREDS1 And AREDS2?"},"content":{"rendered":"
Age-related macular degeneration (AMD) is a significant cause of vision loss, affecting millions worldwide. To address this, the National Eye Institute<\/a> conducted the Age-Related Eye Disease Studies (AREDS and AREDS2). These studies aimed to investigate the effects of vitamins and minerals on the progression of AMD. This article delves into the nuances of both studies, highlighting the differences and their implications for eye health.<\/span><\/p>\n Age-related macular degeneration<\/a> is a condition that deteriorates the macula, the central part of the retina responsible for sharp and detailed vision. AMD can be classified into two types: dry (atrophic) and wet (neovascular). Dry AMD is more common and less severe but can progress to the wet type, which can lead to rapid vision loss<\/a>.<\/span><\/p>\n The first Age-Related Eye Disease Study (AREDS1) was launched in 1992 and concluded in 2001. It involved over 3,600 participants aged 55 to 80 years who were at varying stages of AMD. The study aimed to explore the effects of a specific combination of antioxidants and zinc on the progression of AMD and cataracts.<\/span><\/p>\n AREDS1 tested a daily supplement containing:<\/span><\/p>\n The study concluded that the AREDS1 formulation significantly reduced the risk of progression to advanced AMD by about 25% over a five-year period<\/a> for participants with high risk of developing advanced stages of the disease. However, it showed no significant effect on the development or progression of cataracts.<\/span><\/p>\n <\/p>\n Based on the findings from AREDS1 and emerging research suggesting potential benefits of other nutrients, the AREDS2 study<\/a> was initiated to refine the original formula. Conducted from 2006 to 2012, AREDS2 aimed to evaluate the effects of adding omega-3 fatty acids, lutein, and zeaxanthin<\/a> to the mix, and to assess the necessity of beta-carotene and zinc levels in the original formula.<\/span><\/p>\n AREDS2 tested several modifications to the AREDS1 formula:<\/span><\/p>\n AREDS2 revealed that adding lutein and zeaxanthin, with or without omega-3 fatty acids, to the AREDS formula made it slightly more effective in reducing the risk of AMD progression. Moreover, the study found that removing beta-carotene<\/a> did not decrease the formula\u2019s effectiveness, which was a crucial finding since beta-carotene supplementation had been associated with an increased risk of lung cancer in smokers.<\/span><\/p>\n The study also indicated that reducing the amount of zinc did not significantly affect the formula\u2019s effectiveness. Therefore, a lower dose might be as beneficial, reducing the potential for side effects linked to high zinc intake.<\/span><\/p>\n The transition from the AREDS1 to AREDS2 study signifies an important evolution in the fight against age-related macular degeneration (AMD). While both studies shared the common goal of identifying effective nutritional strategies to slow the progression of AMD, there were notable differences in their formulations, findings, and subsequent recommendations for eye health.<\/span><\/p>\n AREDS1<\/b> focused on a formulation that included high doses of antioxidants and zinc. This combination was chosen based on the hypothesis that oxidative stress plays a key role in the development and progression of AMD. The significant finding from AREDS1 was that the formulation could reduce the risk of progression to advanced AMD by about 25% for individuals at high risk.<\/span><\/p>\n AREDS2<\/b> sought to build upon these findings by assessing the potential benefits of adding or modifying components in the original formula. Key changes included:<\/span><\/p>\n These modifications reflect a nuanced understanding of nutritional science and its application to eye health, particularly in the context of AMD management.<\/span><\/p>\n <\/p>\n The findings from AREDS2 have significant implications for the management of AMD and potentially other eye conditions influenced by nutritional status. Firstly, the shift towards a safer formulation that excludes beta-carotene lowers the risk for smokers or former smokers, expanding the population that can safely use the supplement<\/a>.<\/span><\/p>\nUnderstanding age-related macular degeneration<\/span><\/h2>\n
The advent of AREDS1<\/span><\/h2>\n
The AREDS1 formulation<\/span><\/h3>\n
\n
Key findings of AREDS1<\/span><\/h3>\n
Transitioning to AREDS2<\/span><\/h2>\n
The AREDS2 formulation<\/span><\/h3>\n
\n
Key findings of AREDS2<\/span><\/h3>\n
Comparing AREDS1 and AREDS2<\/span><\/h2>\n
\n
Implications for eye health<\/span><\/h2>\n